ArticleCarcinogenesis2016
Vitamin D receptor polymorphisms and survival in patients with cutaneous melanoma: a population-based study.
Article in Carcinogenesis, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Role of VDR gene polymorphisms and environmental factors in the development of skin cancers: evidence by updated meta-analysis.Archives of dermatological research · 2025Pooled it
- 25-Hydroxyvitamin D status, vitamin D intake, and skin cancer risk: a systematic review and dose-response meta-analysis of prospective studies.Scientific reports · 2020Pooled it
- The impact of vitamin D pathway genetic variation and circulating 25-hydroxyvitamin D on cancer outcome: systematic review and meta-analysis.British journal of cancer · 2017Pooled it
- Vitamin D Supplementation and Disease-Free Survival in Stage II Melanoma: A Randomized Placebo Controlled Trial.Nutrients · 2021Trial
- Trial
- 25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial.British journal of cancer · 2018Trial
- Association of chemokine and chemokine receptor gene variants with occurrence of multiple primary melanoma.Melanoma research · 2026Article
- Association of serum vitamin D and serum vitamin C with the risk of melanoma among adults in the United States: a cross-sectional analysis of 2003-2006 and 2017-2018 NHANES data.Journal of clinical biochemistry and nutrition · 2026Article
- Genetic Landscape of Familial Melanoma.Genes · 2025Review
- Cognitive function is mediated by deficit accumulation in older, long-term breast cancer survivors.Journal of cancer survivorship : research and practice · 2024Article
- Review
- The impact of APOE and smoking history on cognitive function in older, long-term breast cancer survivors.Journal of cancer survivorship : research and practice · 2024Article
- Association of Vitamin D receptor gene variations with Gastric cancer risk in Kashmiri population.Molecular biology reports · 2021Article
- Germline variants are associated with increased primary melanoma tumor thickness at diagnosis.Human molecular genetics · 2021Article
- Vitamin D Receptor Polymorphisms and Non-Melanoma Skin Cancer Risk: A Case-Control Study.Journal of clinical medicine · 2020Article
- Current Molecular Markers of Melanoma and Treatment Targets.International journal of molecular sciences · 2020Review
- Serum Total 25-Hydroxyvitamin D Levels in Patients With Cutaneous Malignant Melanoma: A Case-Control Study in a Low-Risk Southern European Population.Dermatology practical & conceptual · 2020Article
- Genetic variants and cognitive functions in patients with brain tumors.Neuro-oncology · 2019Article
- Relationship of Chromosome Arm 10q Variants to Occurrence of Multiple Primary Melanoma in the Population-Based Genes, Environment, and Melanoma (GEM) Study.The Journal of investigative dermatology · 2019Article
- Vitamin D receptor polymorphisms and melanoma.Oncology letters · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
Factors known to affect melanoma survival include age at presentation, sex and tumor characteristics. Polymorphisms also appear to modulate survival following diagnosis. Result from other studies suggest that vitamin D receptor (VDR) polymorphisms (SNPs) impact survival in patients with glioma, renal cell carcinoma, lung, breast, prostate and other cancers; however, a comprehensive study of VDR polymorphisms and melanoma-specific survival is lacking. We aimed to investigate whether VDR genetic variation influences survival in patients with cutaneous melanoma. The analysis involved 3566 incident single and multiple primary melanoma cases enrolled in the international population-based Genes, Environment, and Melanoma Study. Melanoma-specific survival outcomes were calculated for each of 38 VDR SNPs using a competing risk analysis after adjustment for covariates. There were 254 (7.1%) deaths due to melanoma during the median 7.6 years follow-up period. VDR SNPs rs7299460, rs3782905, rs2239182, rs12370156, rs2238140, rs7305032, rs1544410 (BsmI) and rs731236 (TaqI) each had a statistically significant (trend P values < 0.05) association with melanoma-specific survival in multivariate analysis. One functional SNP (rs2239182) remained significant after adjustment for multiple testing using the Monte Carlo method. None of the SNPs associated with survival were significantly associated with Breslow thickness, ulceration or mitosis. These results suggest that the VDR gene may influence survival from melanoma, although the mechanism by which VDR exerts its effect does not seem driven by tumor aggressiveness. Further investigations are needed to confirm our results and to understand the relationship between VDR and survival in the combined context of tumor and host characteristics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.